T Conroy

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy Cedex, France
    J Clin Oncol 23:1228-36. 2005
  2. ncbi request reprint Activity of vinorelbine in gastrointestinal cancers
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 6 avenue de Bourgogne, 54511 Vandoeuvre les Nancy Cedex, France
    Crit Rev Oncol Hematol 42:173-8. 2002
  3. doi request reprint FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
  4. pmc Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients
    Johannes M Giesinger
    Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
    Health Qual Life Outcomes 9:19. 2011
  5. ncbi request reprint Quality of life in patients with advanced colorectal cancer: what has been learnt?
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Eur J Cancer 39:287-94. 2003
  6. ncbi request reprint Health-related quality of life in colorectal cancer patients
    Thierry Conroy
    Medical Oncology Department and EA 3444, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Expert Rev Anticancer Ther 3:493-504. 2003
  7. pmc Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
    T Conroy
    Centre Alexis Vautrin, Department of Medical Oncology, Nancy University, 6 avenue de Bourgogne, 54511 Vandœuvre lès Nancy Cedex 54511, France
    Br J Cancer 103:1349-55. 2010
  8. ncbi request reprint French version of FACT-G: validation and comparison with other cancer-specific instruments
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 54500 Vandoeuvre les Nancy, France
    Eur J Cancer 40:2243-52. 2004
  9. pmc Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
    T Conroy
    Centre Alexis Vautrin and Nancy University, EA 4360, Vandoeuvre lès Nancy 54511, France
    Br J Cancer 102:59-67. 2010
  10. ncbi request reprint Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice?
    Thierry Conroy
    Department of Medical Oncology, Alexis Vautrin Centre and EA 4003, Nancy University, Vandoeuvre les Nancy, France
    Curr Opin Oncol 19:401-6. 2007

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy Cedex, France
    J Clin Oncol 23:1228-36. 2005
    ..To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA)...
  2. ncbi request reprint Activity of vinorelbine in gastrointestinal cancers
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 6 avenue de Bourgogne, 54511 Vandoeuvre les Nancy Cedex, France
    Crit Rev Oncol Hematol 42:173-8. 2002
    ..The response rate was 37% (95% CI, 26-49%) with a median duration of response of 7.7 months. This 2-day regimen appears at least as active and less toxic than the standard 5-day 5-FU and cisplatin regimen...
  3. doi request reprint FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
    ....
  4. pmc Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients
    Johannes M Giesinger
    Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
    Health Qual Life Outcomes 9:19. 2011
    ..These new CAT measures are conceptualised to reflect the same constructs as the QLQ-C30 scales. Accordingly, the Fatigue-CAT is intended to capture physical and general fatigue...
  5. ncbi request reprint Quality of life in patients with advanced colorectal cancer: what has been learnt?
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Eur J Cancer 39:287-94. 2003
    ..An international consensus on the methods of measurement of HRQoL in oncology is warranted to enhance compliance, to better interpret results and to optimise the publication of precise HRQoL data...
  6. ncbi request reprint Health-related quality of life in colorectal cancer patients
    Thierry Conroy
    Medical Oncology Department and EA 3444, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Expert Rev Anticancer Ther 3:493-504. 2003
    ..An international consensus involving clinicians and methodologists is needed to describe robust standards for quality of life measurement in oncology...
  7. pmc Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
    T Conroy
    Centre Alexis Vautrin, Department of Medical Oncology, Nancy University, 6 avenue de Bourgogne, 54511 Vandœuvre lès Nancy Cedex 54511, France
    Br J Cancer 103:1349-55. 2010
    ..A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil...
  8. ncbi request reprint French version of FACT-G: validation and comparison with other cancer-specific instruments
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, 54500 Vandoeuvre les Nancy, France
    Eur J Cancer 40:2243-52. 2004
    ..Use of the specific H&N additional items increased the responsiveness to change of FACT-G. The French version of FACT-G is valid and has psychometric properties similar to those of FLIC and QLQ-C30...
  9. pmc Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
    T Conroy
    Centre Alexis Vautrin and Nancy University, EA 4360, Vandoeuvre lès Nancy 54511, France
    Br J Cancer 102:59-67. 2010
    ..A secondary objective was to compare the quality of life (QoL) and health-care satisfaction of patients...
  10. ncbi request reprint Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice?
    Thierry Conroy
    Department of Medical Oncology, Alexis Vautrin Centre and EA 4003, Nancy University, Vandoeuvre les Nancy, France
    Curr Opin Oncol 19:401-6. 2007
    ..We review recent literature to evaluate whether quality-of-life assessment contributes to optimal patient information and helps treatment choices...
  11. ncbi request reprint Quality of life in patients with oesophageal and gastric cancer: an overview
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Oncology 70:391-402. 2006
    ..This article reviews the impact of surgery and reconstructive techniques, as well as of adjuvant and palliative treatments on the QoL of patients with OGC...
  12. doi request reprint Metastatic pancreatic cancer: old drugs, new paradigms
    Thierry Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Nancy University, Vandoeuvre les Nancy, France
    Curr Opin Oncol 23:390-5. 2011
    ..In this article, we will review current first-line treatments for metastatic pancreatic adenocarcinoma focusing on randomized studies...
  13. ncbi request reprint [Measure of quality of life in patients with metastatic colorectal cancer: techniques and main results]
    T Conroy
    Departement d Oncologie Medicale, Centre Alexis Vautrin, UPRES EA 1124 Epidémiologie clinique, prévention et qualité de vie Ecole de santé publique, Faculte de Medecine, Vandoeuvre les Nancy, France
    Rev Med Interne 23:703-16. 2002
    ..The aim of this article is to provide an overview of the instruments used to measure quality of life in patients with metastatic colorectal cancer, to review the published data and to analyse the bias and methodological problems...
  14. ncbi request reprint Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Ann Oncol 13:721-9. 2002
    ....
  15. ncbi request reprint High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study
    D Peiffert
    Centre Alexis Vautrin, Nancy, France
    Ann Oncol 12:397-404. 2001
    ..To analyse toxicity and response to a new scheme of neoadjuvant chemotherapy (CT) and concomitant radiochemotherapy (RT-CT) for locally advanced anal canal squamous-cell carcinoma (ACC)...
  16. ncbi request reprint Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer
    M C Kaminsky-Forrett
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Int J Radiat Oncol Biol Phys 42:935-41. 1998
    ..To evaluate the prognostic value of tumor downstaging after preoperative radiation for resectable rectal cancer...
  17. pmc Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
    T Conroy
    1Department of Medical Oncology and Radiotherapy, EA 4003, Nancy University and Centre Alexis Vautrin, 6 avenue de Bourgogne, 54511 Vandoeuvre les Nancy, France
    Br J Cancer 99:1395-401. 2008
    ..5%, including 12% complete response. Response rate on primary tumour was 62.9%. This FOLFOX-4 regimen was reasonably well tolerated and effective in inoperable/metastatic oesophageal carcinoma and warrants additional investigation...
  18. doi request reprint Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
    D Malka
    Gastrointestinal Oncology Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:919-27. 2012
    ..We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients...
  19. doi request reprint Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C
    Christine Rotonda
    Nancy University, EA 4003, 54000 Vandoeuvre les Nancy, France
    Qual Life Res 17:437-45. 2008
    ....
  20. ncbi request reprint Factors affecting local control and survival after treatment of carcinoma of the rectum by endocavitary radiation: a retrospective study of 97 cases
    P Rauch
    Department of Surgery, Centre Alexis Vautrin, Vandoeuvre, France
    Int J Radiat Oncol Biol Phys 49:117-24. 2001
    ..We studied the prognostic factors for locoregional or metastatic relapse after endocavitary radiation, and their impact for therapeutic strategy...
  21. doi request reprint Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: the FATSEIN study
    C Rotonda
    INSERM, CIC EC CIE6, Nancy, France
    Contemp Clin Trials 32:244-9. 2011
    ..Fatigue is now considered as the most distressing side effect of treatment. Fifty-eight percent to 94% of breast cancer patients experience fatigue during treatment with adjuvant chemotherapy...
  22. ncbi request reprint A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable
    F Bonnetain
    Fédération Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d Arc, 21079 Dijon Cedex, France
    Ann Oncol 17:827-34. 2006
    ....
  23. ncbi request reprint High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
    J Y Blay
    Centre Leon Berard, Lyon, France
    J Clin Oncol 16:864-71. 1998
    ..The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression...
  24. ncbi request reprint Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
    R Fety
    Centre Rene Gauducheau, Nantes, France
    Clin Cancer Res 4:2039-45. 1998
    ..7% in the PK-arm. The present study is the first to demonstrate, in a randomized design, the clinical interest of an individual 5FU dose adaptation based on pharmacokinetic survey, in terms of therapeutic index improvement...
  25. ncbi request reprint An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
    M Ychou
    Centre Val d Aurelle, Montpellier, France
    Ann Oncol 14:481-9. 2003
    ..The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of irinotecan and oxaliplatin with a fixed 5-fluorouracil (5-FU)/leucovorin (LV) regimen in patients with metastatic solid tumors...
  26. doi request reprint Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6
    G Perrocheau
    Centre Rene Gauducheau, centre d investigation clinique, Saint Herblain, France
    Oncology 79:174-80. 2010
    ..The objective of this additional analysis was to compare the cost of XELOX and FOLFOX-6...
  27. doi request reprint A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
    M Ychou
    Centre de Recherche et de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Ann Oncol 20:674-80. 2009
    ..This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse...
  28. doi request reprint Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
    Marc Ychou
    Centre Regional de Lutte contre le Cancer Val d Aurelle, 298 rue des apothicaires 34298 Montpellier Cedex 05, France
    J Clin Oncol 29:1715-21. 2011
    ..This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma...
  29. ncbi request reprint Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203
    Jean Pierre Gerard
    Centre Antoine Lacassagne, Radiotherapy Department, Nice, France
    J Clin Oncol 24:4620-5. 2006
    ..In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy...
  30. ncbi request reprint Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2
    Jean Pierre Gerard
    Centre Antoine Lacassagne, 06189 Nice Cedex 2, France
    J Clin Oncol 28:1638-44. 2010
    ..Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin...
  31. ncbi request reprint [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]
    Thierry Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 91:759-68. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  32. ncbi request reprint Quality of life among disease-free survivors of rectal cancer
    Philippe Rauch
    Surgical Department and Medical Oncology, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy, France
    J Clin Oncol 22:354-60. 2004
    ..To identify factors affecting the quality of life (QoL) of disease-free survivors of rectal cancer...
  33. ncbi request reprint Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study
    Eric Francois
    Department of Medical Oncology, Centre Antoine Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
    Eur J Cancer 41:2861-7. 2005
    ..The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies...
  34. ncbi request reprint [Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review]
    Célia Roemer-Becuwe
    Departement d Oncologie Medicale, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy
    Bull Cancer 90:1097-105. 2003
    ..Because of a lack of systemic data, reliable analysis of the results is difficult. Several questions remain open about which bisphosphonates and route of administration to choose, and the variable effects on different primaries...
  35. ncbi request reprint [Quality of life measurement in cancer survivors]
    Simon Schraub
    Centre de Lutte Contre le Cancer Paul Strauss, 3, rue de la Porte de l Hôpital, 67085 Strasbourg Cedex, France
    Bull Cancer 89:267-74. 2002
    ..QOL can be evaluated in a cohort of patients in a longitudinally study or better in a case control study. Examples of QOL evaluation of different cancers sites are given...
  36. ncbi request reprint Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology
    Franck Bonnetain
    INSERM EMI 106 and Federation Francophone de Cancerologie Digestive, Faculty of Medicine, 7 bd Jeanne d Arc, BP 879000, 21079 Dijon Cedex
    Gastroenterol Clin Biol 29:1113-24. 2005
    ..The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma...
  37. ncbi request reprint [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]
    L Tournier-Rangeard
    Département de radiothérapie et curiethérapie, Centre Alexis Vautrin, Avenue de Bourgogne, 54511 Vandoeuvre les Nancy Cedex, France
    Cancer Radiother 11:169-77. 2007
    ..To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution...
  38. pmc Late cardiopulmonary toxicity after treatment for Hodgkin's disease
    C Allavena
    Centre Alexis Vautrin, Department of Radiotherapy, , France
    Br J Cancer 65:908-12. 1992
    ..We conclude that the treatment with mantle field under good technical conditions (high energy photons, moderate doses...) can result in minimal cardiopulmonary dysfunction...
  39. ncbi request reprint [Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer]
    T Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 93:197-200. 2006
  40. ncbi request reprint Quality of life in long-term survivors of oropharynx carcinoma
    Nicolas Pourel
    Department of Radiation Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Int J Radiat Oncol Biol Phys 54:742-51. 2002
    ..To collect data on the health-related quality of life (QOL) of long-term survivors and to determine to what extent QOL might be an appropriate end point in the comparison of treatment options in oropharyngeal carcinoma...
  41. ncbi request reprint Surgical resection with and without chemotherapy in oesophageal cancer
    Jean Francois Bosset
    Lancet 360:1173-4; author reply 1175. 2002
  42. ncbi request reprint Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
    Fabio Efficace
    European Organisation for Research and Treatment of Cancer EORTC, EORTC Data Center, Quality of Life Unit, Avenue E Mounier 83, 1200 Brussels, Belgium
    Eur J Cancer 42:42-9. 2006
    ..The results suggest that social functioning, acts as a prognostic measure of survival beyond a number of previously known biomedical parameters...
  43. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
    ..The present studies further characterize efficacy and safety of the XELOX regimen...
  44. ncbi request reprint [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]
    Marc Ychou
    Centre Val d Aurelle, Montpellier
    Bull Cancer 92:381-409. 2005
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  45. ncbi request reprint Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial
    Bernard Nordlinger
    Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris, 9 avenue Charles de Gaulle, Boulogne Billancourt Cedex 92104, France
    Lancet Oncol 6:459-68. 2005
    ..The study also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole...
  46. ncbi request reprint Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study
    Chris J Twelves
    University of Leeds and Bradford NHS Hospitals Trust, United Kingdom
    Clin Colorectal Cancer 5:101-7. 2005
    ..Capecitabine/oxaliplatin (XelOx) is a safe and active combination for the first-line treatment of metastatic CRC...
  47. ncbi request reprint Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach
    Pernilla Lagergren
    Department of Social Medicine at South Bristol, University of Bristol, Bristol, United Kingdom
    Eur J Cancer 43:2066-73. 2007
    ..To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach...
  48. ncbi request reprint Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102
    Laurent Bedenne
    University Hospital Le Bocage, Dijon, France
    J Clin Oncol 25:1160-8. 2007
    ..Therefore, a randomized trial was carried out to compare, in responders only, chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors...
  49. ncbi request reprint Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer
    Catherine Lejeune
    INSERM EMI Equipe Mixte INSERM 0106, Dijon, France
    J Nucl Med 46:2020-8. 2005
    ..This study was designed to assess the cost-effectiveness of PET in the diagnosis and staging of patients with metachronous liver metastases of colorectal cancer using a decision analysis model...
  50. ncbi request reprint Metastatic colorectal cancer
    Olivier Bouche
    Service d Hepato Gastroenterologie, CHU Robert Debre, Reims
    Gastroenterol Clin Biol 30:2S30-2S42. 2006
  51. doi request reprint Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer
    Mohamed Hebbar
    Medical Oncology Unit, University Hospital, Lille, France
    Oncology 73:185-91. 2007
    ..To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer...
  52. ncbi request reprint Use of differential item functioning analysis to assess the equivalence of translations of a questionnaire
    Morten Aa Petersen
    Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark
    Qual Life Res 12:373-85. 2003
    ..We conclude that testing for DIF is a useful way to validate questionnaire translations...